VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | CAR-T and antibody developments: aggressive lymphomas

Nilanjan Ghosh MD, PhD, of Levine Cancer Institute, Charlotte, NC, discusses novel developments in cellular and bispecific antibody therapies for aggressive lymphomas. Specifically discussed is AUTO3, a CAR-T cell therapy targeting CD19 and CD22, that has been investigated in combination with pembrolizumab. Furthermore, Dr Ghosh highlights glofitamab, an anti-CD20/CD3 bispecific antibody evaluated in relapsed/refractory B-cell non-Hodgkin’s lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter